New pyrimido-indole compound CD-160130 preferentially inhibits the Kv11.1B isoform and produces antileukemic effects without cardiotoxicity

Molecular Pharmacology

Volumn 87, Issue 2, 2015, Pages 183-196

  Gasparoli, Luca ^a   D'Amico, Massimo ^c   Masselli, Marika ^b,c   Pillozzi, Serena ^a   Caves, Rachel ^d   Khuwaileh, Rawan ^d   Tiedke, Wolfgang ^e   Mugridge, Kenneth ^e   Pratesi, Alessro ^b   Mitcheson, John S ^d   Basso, Giuseppe ^f   Becchetti, Andrea ^g   Arcangeli, Annarosa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c DIVAL Toscana Srl   (Italy)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e BlackSwan Pharma GmbH   (Germany)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CALCIUM ACTIVATED POTASSIUM CHANNEL; CD 160130; CYTARABINE; DOXORUBICIN; FLUDARABINE; INDOLE DERIVATIVE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCA3.1; POTASSIUM CHANNEL KV1.3; POTASSIUM CHANNEL KV1.5; POTASSIUM CHANNEL KV11.1A; POTASSIUM CHANNEL KV11.1B; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARDIOTOXIN; CD-160130; ERG1 POTASSIUM CHANNEL; ISOPROTEIN; PYRIMIDINONE DERIVATIVE;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW TOXICITY; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; ELECTRIC POTENTIAL; FEMALE; GENE EXPRESSION; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA; LEUKEMIA CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; POTASSIUM CURRENT; QT INTERVAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG SCREENING; HAMSTER; HEK293 CELL LINE; HL 60 CELL LINE; LEUKEMIA, B-CELL; METABOLISM; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOTOXINS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GUINEA PIGS; HEK293 CELLS; HL-60 CELLS; HUMANS; INDOLES; LEUKEMIA, B-CELL; MALE; MICE; PROTEIN ISOFORMS; PYRIMIDINES; PYRIMIDINONES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919772674     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.094920     Document Type: Article

References (46)

1. Arcangeli A (2005) Expression and role of hERG channels in cancer cells. Novartis Found Symp 266:225-232; discussion 232-224.
2. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, and Becchetti A (2009) Targeting ion channels in cancer: A novel frontier in antineoplastic therapy. Curr Med Chem 16: 66-93.
3. Arcangeli A, Pillozzi S, and Becchetti A (2012) Targeting ion channels in leukemias: A new challenge for treatment. Curr Med Chem 19:683-696.
4. Crociani O, Guasti L, Balzi M, Becchetti A, Wanke E, Olivotto M, Wymore RS, and Arcangeli A (2003) Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J Biol Chem 278:2947-2955.
5. Crociani O, Zanieri F, Pillozzi S, Lastraioli E, Stefanini M, Fiore A, Fortunato A, D'Amico M, Masselli M, and De Lorenzo E et al. (2013) hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. Sci Rep 3:3308.
6. Dalton WT, Jr, Ahearn MJ, McCredie KB, Freireich EJ, Stass SA, and Trujillo JM (1988) HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 71:242-247.
7. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, and Leufkens HG (2005) Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26:590-597.
8. Faravelli L, Arcangeli A, Olivotto M, and Wanke E (1996) A HERG-like K1 channel in rat F-11 DRG cell line: Pharmacological identification and biophysical characterization. J Physiol 496:13-23.
9. Guasti L, Crociani O, Redaelli E, Pillozzi S, Polvani S, Masselli M, Mello T, Galli A, Amedei A, and Wymore RS et al. (2008) Identification of a posttranslational mechanism for the regulation of hERG1 K1 channel expression and hERG1 current density in tumor cells. Mol Cell Biol 28: 5043-5060.
10. Hauser DS, Stade M, Schmidt A, and Hanauer G (2005) Cardiovascular parameters in anaesthetized guinea pigs: A safety pharmacology screening model. J Pharmacol Toxicol Methods 52:106-114.
11. Jehle J, Schweizer PA, Katus HA, and Thomas D (2011) Novel roles for hERG K 1 channels in cell proliferation and apoptosis. Cell Death Dis 2:e193.
12. Jones EM, Roti Roti EC, Wang J, Delfosse SA, and Robertson GA (2004) Cardiac IKr channels minimally comprise hERG 1a and 1b subunits. J Biol Chem 279: 44690-44694.
13. Kamiya K, Niwa R, Mitcheson JS, and Sanguinetti MC (2006) Molecular determinants of HERG channel block. Mol Pharmacol 69:1709-1716.
14. Kim DH and Lerner A (1998) Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 92: 2484-2494.
15. Larsen AP and Olesen SP (2010) Differential expression of hERG1 channel isoforms reproduces properties of native IKr and modulates cardiac action potential characteristics. PLoS ONE 5:e9021.
16. Lees-Miller JP, Kondo C, Wang L, and Duff HJ (1997) Electrophysiological characterization of an alternatively processed ERG K1 channel in mouse and human hearts. Circ Res 81:719-726.
17. Lerner A and Epstein PM (2006) Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 393:21-41.
18. Levesque MC, O'Loughlin CW, and Weinberg JB (2001) Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture. Leukemia 15: 1305-1307.
19. Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, Buccoliero AM, Paglierani M, Pollo B, Taddei GL, Gallina P et al. (2005) hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer 93:781-92.
20. Mitchell GF, Jeron A, and Koren G (1998) Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol 274:H747-H751.
21. Morais Cabral JH, Lee A, Cohen SL, Chait BT, Li M, and Mackinnon R (1998) Crystal structure and functional analysis of the HERG potassium channel N terminus: A eukaryotic PAS domain. Cell 95:649-655.
22. Morissette P, Nishida M, Trepakova E, Imredy J, Lagrutta A, Chaves A, Hoagland K, Hoe CM, Zrada MM, Travis JJ et al. (2013) The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model J Pharmacol Toxicol Methods 68:137-49.
23. Pelliccia F, Ubertini V, and Bosco N (2012) The importance of molecular cytogenetic analysis prior to using cell lines in research: The case of the KG-1a leukemia cell line. Oncol Lett 4:237-240.
24. Pier DM, Shehatou GS, Giblett S, Pullar CE, Trezise DJ, Pritchard CA, Challiss RA, and Mitcheson JS (2014) Long-term channel block is required to inhibit cellular transformation by human ether-à-go-go-related gene (hERG1) potassium channels. Mol Pharmacol 86:211-221.
25. Pillozzi S, Accordi B, Rebora P, Serafin V, Valsecchi MG, Basso G, and Arcangeli A (2014) Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups. Leukemia 28: 1352-1355.
26. Pillozzi S, Brizzi MF, Balzi M, Crociani O, Cherubini A, Guasti L, Bartolozzi B, Becchetti A, Wanke E, and Bernabei PA et al. (2002) HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 16:1791-1798.
27. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, Boddi V, Pegoraro L, Becchetti A, and Arcangeli A (2007) VEGFR-1 (FLT-1), b1 integrin, and hERG K1 channel for a macromolecular signaling complex in acute myeloid leukemia: Role in cell migration and clinical outcome. Blood 110:1238-1250.
28. Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O, Amedei A, Veltroni M, D'Amico M, and Basso G et al. (2011) Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 117:902-914.
29. Pond AL, Scheve BK, Benedict AT, Petrecca K, Van Wagoner DR, Shrier A, and Nerbonne JM (2000) Expression of distinct ERG proteins in rat, mouse, and human heart. Relation to functional IKr channels. J Biol Chem 275:5997-6006.
30. Pui CH and Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178.
31. Raschi E, Vasina V, Poluzzi E, and De Ponti F (2008) The hERG K1 channel: Target and antitarget strategies in drug development. Pharmacol Res 57:181-195.
32. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, and Wallis R et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45.
33. Reichelt C, Schulze A, Daghish M, Ludwig FA, Heinicke J, Herrmann K, Schuster M, Letschert S, Mugridge K, and DeAngelo J (2014) inventors, The Medicines Company (Leipzig) Gmbh, assignee. Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system. Patent 8664233, 2014 Mar 4.
34. Sale H, Wang J, O'Hara TJ, Tester DJ, Phartiyal P, He JQ, Rudy Y, Ackerman MJ, and Robertson GA (2008) Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with long-QT syndrome. Circ Res 103:e81-e95.
35. Sanguinetti MC, Jiang C, Curran ME, and Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299-307.
36. Sanguinetti MC and Mitcheson JS (2005) Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26:119-124.
37. Sanguinetti MC and Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463-469.
38. Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R, and Wulff H (2009) Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75: 281-295.
39. Smith GA, Tsui HW, Newell EW, Jiang X, Zhu XP, Tsui FW, and Schlichter LC (2002) Functional up-regulation of HERG K1 channels in neoplastic hematopoietic cells. J Biol Chem 277:18528-18534.
40. Spector PS, Curran ME, Zou A, Keating MT, and Sanguinetti MC (1996) Fast inactivation causes rectification of the IKr channel. J Gen Physiol 107:611-619.
41. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, and Andreeff M et al. (2007) Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67:684-694.
42. Trudeau MC, Warmke JW, Ganetzky B, and Robertson GA (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269:92-95.
43. Tseng GN (2001) IKr: The hERG channel. J Mol Cell Cardiol 33:835-849.
44. Viskin S (1999) Long QT syndromes and torsade de pointes. Lancet 354:1625-1633.
45. Weinberg J.B. , Jiang N., Volkheimer A.D., Chen Y., Bond K.M., Moore J.O., Gockerman J.P., Diehl L.F., de Castro C.M., and Rizzieri D.A.et al. (2007) Cytotoxicity of the type 4 phosphodiesterase inhibitor CD160130 for freshly isolated human CLL cells in vitro. Blood 110:920a.
46. Zimin PI, Garic B, Bodendiek SB, Mahieux C, Wulff H, and Zhorov BS (2010) Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Mol Pharmacol 78:588-599.